Interleukin 5 News and Research

RSS

Researchers identify interferons may inhibit IL-1b protein production

Among the first is the production of cell factors such as interferons and IL-1beta. Interferons have several functions, including activating a series of intracellular signals such as Tyk2 (Tyrosine kinase 2), while IL-1beta is important for the induction of inflammation, which helps directly to protect the body against attack.

16 Sep 2010

Promising skin cancer drug in the near horizon

A new drug has been developed to combat a deadly form of skin cancer – melanoma. The drug, PLX4032, was tested on 32 melanoma patients who had a key mutation in their tumors. 26 of these patients responded favorably says the study published in the New England Journal of Medicine.

30 Aug 2010

Scientists identify genetic basis to determine severity of allergic asthma in experimental models

Scientists have identified a genetic basis for determining the severity of allergic asthma in experimental models of the disease.The study may help in the search for future therapeutic strategies to fight a growing medical problem that currently lacks effective treatments, researchers from Cincinnati Children's Hospital Medical Center report in the Aug. 29 Nature Immunology.

30 Aug 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

Second-hand smoke triggers complex inflammatory response

Second-hand smoke is associated with a number of diseases and conditions, including cancer, heart disease, and emphysema. It is an irritant to lung tissue and blood vessels, but the processes through which the body reacts to second-hand smoke comprise a mystery scientists are only beginning to unravel. Researchers at the University of Colorado-Denver are currently studying how second-hand smoke affects the lungs of rats, and so far it appears that second-hand smoke triggers a complex inflammatory response.

27 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

Novartis presents 2010 Immunology prizes at 16th International Congress of Immunology in Kobe

The Novartis 2010 Immunology Prizes were presented at the 16th International Congress of Immunology in Kobe, Japan. Since 1992, the Novartis Prizes for Immunology have been awarded every third year for outstanding contributions to basic and clinical immunology. The prizes recognize individual achievement and provide financial support for further research by the recipients. The prizes are a major feature of the triennial International Congress of Immunology.

24 Aug 2010

Epicept receives refusal to file letter on new drug application

EpiCept Corporation today announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene(histamine dihydrochloride).

23 Aug 2010

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Scientists at the University Medical Center of Johannes Gutenberg University Mainz, Germany have taken a further step towards improving our understanding of how asthma develops. These new findings show that the gene-regulating molecule "IRF4" plays a key role in the development of T helper 9 lymphocytes (Th9 cells), which can play a major part in the development of this chronic, inflammatory illness of the respiratory tract.

18 Aug 2010

Interleukin Genetics transfers stock trading from NYSE Amex to OTCQB Marketplace

Interleukin Genetics, Inc. today announced that trading of shares of the Company's common stock will be transferred from the NYSE Amex to the OTCQB™ Marketplace effective today, August 16, 2010. Investors in the Company can trade the stock easily in this marketplace, where Interleukin Genetics' symbol will now be ILIU.

16 Aug 2010

Adverse effects in childhood lead to immune impairment later in life

The emotional pains we suffer in childhood can lead to weakened immune systems later in life, according to a new study.Based on this new research, the amount of this immune impairment even enhances that caused by the stress of caregiving later in life."What happens in childhood really matters when it comes to your immune response in the latter part of your life," explained Janice Kiecolt-Glaser, professor of psychology and psychiatry at Ohio State University. She explained her work at the annual meeting of the American Psychological Association in San Diego.

16 Aug 2010

Interleukin Genetics second-quarter net loss from continuing operations decreases to $1.9 million

Interleukin Genetics, Inc. today announced financial and operational results for the second quarter ended June 30, 2010.

13 Aug 2010

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

University of Michigan School of Dentistry has signed an agreement with Interleukin Genetics Inc. to conduct what may be the largest clinical study to date using genetic testing to assess the risk for gum disease.

13 Aug 2010

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

Infections like the flu are common occurrences during pregnancy, and research has shown that children born to mothers who suffered from flu, viruses and other infections during pregnancy have about a 1.5 to 7 times increased risk for schizophrenia. A new study out of Temple University examines what's behind that link.

13 Aug 2010

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.

12 Aug 2010

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Aug 2010

UCLA study identifies neurocognitive pathways involved in inflammatory responses to acute social stress

Everyone experiences social stress, whether it is nervousness over a job interview, difficulty meeting people at parties, or angst over giving a speech. In a new report, UCLA researchers have discovered that how your brain responds to social stressors can influence the body's immune system in ways that may negatively affect health.

10 Aug 2010

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

9 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Interleukin 5 News and Research

Researchers identify interferons may inhibit IL-1b protein production

Promising skin cancer drug in the near horizon

Scientists identify genetic basis to determine severity of allergic asthma in experimental models

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

Second-hand smoke triggers complex inflammatory response

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Novartis presents 2010 Immunology prizes at 16th International Congress of Immunology in Kobe

Epicept receives refusal to file letter on new drug application

Gene-regulating molecule plays key role in development of Th9 cells linked to chronic respiratory tract illness

Interleukin Genetics transfers stock trading from NYSE Amex to OTCQB Marketplace

Adverse effects in childhood lead to immune impairment later in life

Interleukin Genetics second-quarter net loss from continuing operations decreases to $1.9 million

U-M dentistry agrees to use Interleukin's PST test for gum disease clinical study

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

UCLA study identifies neurocognitive pathways involved in inflammatory responses to acute social stress

Apte wins Elkeles Prize for outstanding scientist in field of medicine

EpiCept second-quarter net loss decreases to $4.9 million

FDA designates XOMA 052 orphan drug for Behcet's disease

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News